Corvus Pharmaceuticals, Inc. (CRVS)
USD 4.7
(-36.4%)
USD 4.7
(-36.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.93 Million | -27.02 Million | -36.71 Million | -34.77 Million | -37.32 Million | -40.98 Million |
| Net Income | -27.02 Million | -41.3 Million | -43.24 Million | -5.99 Million | -46.67 Million | -46.93 Million |
| Depreciation & Amortization | 151 Thousand | 367 Thousand | 460 Thousand | 632 Thousand | 743 Thousand | 847 Thousand |
| Deferred income taxes | -111 Thousand | - | - | - | - | - |
| Stock-based compensation | 2.14 Million | 2.69 Million | 4.23 Million | 5.74 Million | 7.34 Million | 7.13 Million |
| Change in working capital | -3.59 Million | 1.41 Million | -3.23 Million | 1.9 Million | 1.9 Million | -1.42 Million |
| Other non-cash items | 4.5 Million | 9.81 Million | 5.07 Million | -37.07 Million | -644 Thousand | -608 Thousand |
| Investing Cash Flow | 15.54 Million | -23.27 Million | 21.56 Million | 44.76 Million | 3.25 Million | -30.19 Million |
| Investments in PPE | -34 Thousand | -269 Thousand | -5000.00 | -76 Thousand | -25 Thousand | -355 Thousand |
| Acquisitions | -15.57 Thousand | 22 Thousand | -21.56 Thousand | -44.84 Thousand | -3280.00 | - |
| Investment purchases | -47.04 Million | -66.19 Million | -9.35 Million | -42.54 Million | -138.58 Million | -161.86 Million |
| Sales/Maturities of investments | 62.62 Million | 43.16 Million | 30.92 Million | 87.38 Million | 141.86 Million | 132.02 Million |
| Other Investing Activities | 15.57 Thousand | -23 Thousand | 21.56 Thousand | 44.84 Thousand | 3280.00 | -29.83 Million |
| Financing Cash Flow | 7.85 Million | - | 62.15 Million | 1.31 Million | 24 Thousand | 65.27 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 7.85 Million | - | 62.15 Million | 1.22 Million | 24 Thousand | 64.87 Million |
| Other Financing Activities | 7.85 Million | - | 62.15 Million | 88 Thousand | 24.00 | 393 Thousand |
| Accounts receivables | 562 Thousand | -81 Thousand | -507 Thousand | - | - | - |
| Accounts payables | -451 Thousand | 411 Thousand | -1.9 Million | 1.01 Million | 450 Thousand | -1.45 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -3.7 Million | 1.08 Million | -827 Thousand | 890 Thousand | 1.45 Million | 33 Thousand |
| Cash at beginning of period | 13.15 Million | 63.45 Million | 16.45 Million | 5.15 Million | 39.19 Million | 45.1 Million |
| Cash at end of period | 12.62 Million | 13.15 Million | 63.45 Million | 16.45 Million | 5.15 Million | 39.19 Million |
| Capital Expenditure | -34 Thousand | -269 Thousand | -5000.00 | -76 Thousand | -25 Thousand | -355 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -539 Thousand | -50.29 Million | 47 Million | 11.3 Million | -34.04 Million | -5.91 Million |
| Free Cash Flow | -23.96 Million | -27.29 Million | -36.72 Million | -34.85 Million | -37.34 Million | -41.34 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.26 Million | -5.7 Million | -6.65 Million | -27.02 Million | -6 Million | -6.5 Million |
| Depreciation & Amortization | 21 Thousand | 23 Thousand | 28 Thousand | 151 Thousand | 30 Thousand | 36 Thousand |
| Deferred income taxes | - | - | -522 Thousand | -111 Thousand | - | - |
| Stock-based compensation | 768 Thousand | 689 Thousand | 572 Thousand | 2.14 Million | 546 Thousand | 537 Thousand |
| Change in working capital | -545 Thousand | 219 Thousand | -391 Thousand | -3.59 Million | -630 Thousand | -319 Thousand |
| Other non-cash items | -248 Thousand | 264 Thousand | 1.79 Million | 4.5 Million | 620 Thousand | 1.02 Million |
| Investing Cash Flow | -17.5 Million | -7000.00 | -2.31 Million | 15.54 Million | 17.54 Million | -4.28 Million |
| Investments in PPE | - | - | - | -34 Thousand | - | - |
| Acquisitions | - | - | 4636.00 | -15.57 Thousand | - | - |
| Investment purchases | -26.29 Million | -4.62 Million | -11.42 Million | -47.04 Million | -1.81 Million | -20.71 Million |
| Sales/Maturities of investments | 8.79 Million | 4.62 Million | 9.1 Million | 62.62 Million | 19.36 Million | 16.43 Million |
| Other Investing Activities | - | -7000.00 | -2318.00 | 15.57 Thousand | 17.54 Thousand | -4289.00 |
| Financing Cash Flow | 30.37 Million | - | - | 7.85 Million | 335 Thousand | 7.51 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 30.37 Million | - | -4000.00 | 7.85 Million | 335 Thousand | 7.51 Million |
| Other Financing Activities | 30.37 Million | - | -3520.00 | 7.85 Million | 335 Thousand | 7.51 Million |
| Accounts receivables | -9000.00 | - | -15 Thousand | 562 Thousand | -11 Thousand | 429 Thousand |
| Accounts payables | -396 Thousand | 84 Thousand | 121 Thousand | -451 Thousand | -694 Thousand | 691 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -140 Thousand | 135 Thousand | -497 Thousand | -3.7 Million | 75 Thousand | -1.43 Million |
| Cash at beginning of period | 7.45 Million | 12.62 Million | 20.1 Million | 13.15 Million | 7.65 Million | 9.65 Million |
| Cash at end of period | 14.84 Million | 7.45 Million | 12.62 Million | 12.62 Million | 20.1 Million | 7.65 Million |
| Capital Expenditure | - | - | - | -34 Thousand | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 7.38 Million | -5.16 Million | -7.48 Million | -539 Thousand | 12.44 Million | -1.99 Million |
| Free Cash Flow | -5.48 Million | -5.15 Million | -5.16 Million | -23.96 Million | -5.43 Million | -5.22 Million |
600558
SGSOF
KISB
LGIH
HRL
0172